Navigation Links
Cepheid Announces Symposium Speakers and Program Highlights for 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Date:4/28/2009

Test for Mycobacterium tuberculosis (TB) Expected to Highlight Broad On-Demand CE IVD Test Menu at Booth #611

SUNNYVALE, Calif., April 28 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) today announced speaker and program highlights for its symposium, "Patient Management in the Era of Rapid Diagnostics," which the company will host at the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), taking place in Finland next month. The company also announced the menu of CE IVD molecular diagnostic tests to be featured in booth #611 on the exhibition floor.

Dr. Fred Tenover, Ph.D., Cepheid's Senior Director of Scientific Affairs, will chair the symposium where leading microbiology and infection control specialists will present data on the clinical impact of rapid, on-demand molecular diagnostic testing.

The Cepheid Symposium, "Patient Management in the Era of Rapid Diagnostics," will take place at 9:00 a.m. on Sunday, 17 May in Hall 3F. The agenda is as follows:

    9:00   MRSA in Paediatric Patients: What Rapid Testing Reveals
           Presented by Dr. Jim Gray, Senior Microbiologist, Birmingham
           Children's Hospital
    9:30   Detecting C. difficile: Slowly or Quickly?
           Presented by Professor Mark Wilcox, Professor in Medical
           Microbiology, Institute of Molecular and Cellular Biology, Leeds
    10:00  Do We Need Rapid Tests to Detect Tuberculosis and Rifampicin
           Resistance?
           Presented by Dr. Sabine Ruesch-Gerdes, National Reference Centre
           for Mycobacteria, Borstel, Germany
    10:30  Will Community MRSA and C. difficile Change Infection Control in
           Hospitals?
           Presented by Dr. Fred Tenover, Cepheid, Sunnyvale, CA

"The 19th ECCMID Congress is shaping up to be extremely interesting in light of recent UK directives from the Department of Health concerning mandatory MRSA screening for all elective admissions and other developments in infection control across Europe," said Dr. David Persing, M.D., Ph.D., Cepheid's Chief Medical and Technology Officer. "Additionally, we expect to showcase our Xpert(R) MTB/RIF test for Mycobacterium tuberculosis - a product that, in my opinion, is one of the most important diagnostic developments to have occurred in many years."

Xpert MTB/RIF not only detects the presence of TB organism directly from sputum in less than two hours, but also identifies whether the strain is resistant to rifampicin, a commonly used first-line drug for treatment of the disease. Many studies have shown that rifampicin resistance is a reliable surrogate marker of strains that are multidrug-resistant TB (MDR-TB), and the frequency of MDR-TB is increasing in the EU. The test is expected to enable clinicians to dramatically improve the way they initially manage tuberculosis by helping them to make the right therapeutic decision on the first day of the initial patient encounter.

Cepheid currently offers European clinicians a broad menu of on-demand molecular diagnostic tests designed to enhance patient management. The full menu of CE IVD tests expected to be available for demonstration at booth #611 include:

  • Xpert(R) MTB/RIF
    • Diagnostic test for the simultaneous detection of Mycobacterium tuberculosis and resistance to rifampicin
  • Xpert(R) C. difficile
    • Diagnostic test for Clostridium difficile infection
  • Xpert(R) vanA/vanB
    • Detection of vanA and vanB, the genes most associated with hospital-acquired vancomycin-resistant enterococci (VRE)
  • Xpert(R) MRSA
    • Surveillance test for nasal carriage of Methicillin-Resistant Staphylococcus aureus
  • Xpert(R) MRSA/SA BC
    • Diagnostic test for Methicillin-Resistant Staphylococcus aureus and S. aureus in positive blood culture bottles
  • Xpert(R) MRSA/SA Nasal
    • Pre-Surgical Nasal Screening Test for Methicillin-Resistant Staphylococcus aureus and S. aureus
  • Xpert(R) MRSA/SA SSTI
    • Diagnostic test for Methicillin-Resistant Staphylococcus aureus and S. aureus in skin and soft tissue
  • Xpert(R) EV
    • Diagnostic test for Enteroviral Meningitis
  • Xpert(R) GBS
    • Test for vaginal carriage of Group B Streptococcus
  • Xpert(R) BCR-ABL Monitor
    • Monitoring test for patients with Chronic Myeloid Leukaemia (CML)

Congress attendees can also look forward to a wide variety of insightful presentations, based on recent studies, highlighting the important role of molecular diagnostics. Presentations include:

  • Dr. Beryl Oppenheim, Director of Infection Prevention and Control, Birmingham City Hospital: Comparison of the performance of four rapid tests against the gold standards of cytotoxicity assay and culture in the diagnosis of Clostridium difficile infection (CDI)
  • Dr. Kathleen Bamford, Reader and Honorary Consultant Medical Microbiologist, Imperial College, London: Evaluation of commercial toxin detection and two nucleic acid amplification tests for the routine detection of Clostridium difficile infection
  • Dr. Andrej Weintraub, Karolinska Institutet, Stockholm: Comparison of a multiplex real-time PCR and the cytotoxicity neutralization assay for the diagnosis of Clostridium difficile infections
  • Dr. Jim Gray, Senior Microbiologist, Birmingham Children's Hospital: Experience with polymerase chain reaction-based methicillin-resistant Staphylococcus aureus screening in paediatrics
  • Dr. Paolo Cavallerio, Ospedale Molinette, Torino, Italy: Molecular assay for the rapid screening of methicillin-resistant S. aureus (MRSA) colonized patients in an Intensive Care Unit
  • Dr. Martin Jones, Cepheid, Sunnyvale, CA: Rapid detection of Mycobacterium tuberculosis and rifampicin-resistance from sputum samples with an easy-to-use PCR test system with near-patient capability

About Cepheid

Cepheid (Nasdaq: CPHD), based in Sunnyvale, Calif., is a molecular diagnostics company that develops, manufactures, and markets fully-integrated systems and tests for genetic analysis in the clinical, industrial and biothreat markets. The company's systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The company's easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification and detection, which enable the analysis of complex biological samples in its proprietary test cartridges. Through its strong molecular biology capabilities, the company is focusing on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market; food, agricultural, and environmental testing in the industrial market; and identifying bio-terrorism agents in the biothreat market. See www.cepheid.com for more information.

    CONTACTS:
    For Media Inquiries:                   For Cepheid Investor Inquiries:
    Jared Tipton                           Jacquie Ross
    Cepheid Corporate Communications       Cepheid Investor Relations
    408-400-8377                           408-400-8329
    jared.tipton@cepheid.com               investor.relations@cepheid.com


'/>"/>
SOURCE Cepheid
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cepheid Reports 2009 First Quarter Results
2. Cepheid Schedules Fiscal 2009 First Quarter Financial Results Announcement and Webcast
3. Cepheid Announces New Diagnostic Technology to Aid World Efforts in Halting the Spread of Mycobacterium Tuberculosis (TB)
4. Cepheid Announces Preliminary 2008 Fourth Quarter and Full Year Revenue Results
5. Cepheid to Webcast Upcoming Financial Presentations
6. Cepheid Accelerates Direct Sales Channel in UK With Pending Acquisition of Medical Distributor Stretton Scientific
7. Cepheid Reports Third Quarter Revenue of $44.9 Million
8. Results of United Kingdom MRSA Surveillance Program Using Cepheid GeneXpert(R) System Demonstrate Benefits of Rapid Testing
9. Cepheid Molecular Diagnostic Test for MRSA and S. aureus Categorized Moderate Complexity by FDA
10. Cepheid Schedules Fiscal 2008 Third Quarter Financial Results Announcement and Webcast
11. Cepheid Receives FDA Clearance for First On-Demand Diagnostic Test for Life-Threatening MRSA and Staphylococcus aureus From Patient Positive Blood Cultures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) is ... treatments and faster cures for prostate cancer. Members of the Class of 2016 ... countries. Read More About the Class of 2016 PCF ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, ... of the Supplyframe Design Lab . Located in Pasadena, Calif., the Design ... of how hardware projects are designed, built and brought to market. , The ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
(Date:6/23/2016)... On Wednesday, June 22, 2016, the NASDAQ Composite ... Jones Industrial Average edged 0.27% lower to finish at 17,780.83; ... has initiated coverage on the following equities: Infinity Pharmaceuticals Inc. ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ), ... more about these stocks by accessing their free trade alerts ...
Breaking Biology Technology:
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... of Infosys (NYSE: INFY ), and Samsung SDS, ... partnership that will provide end customers with a more ... payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) ... financial services, but it also plays a fundamental part in ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys ... founding CEO, Barrett Bready , M.D., who returned ... of the original technical leadership team, including Chief Technology ... of Product Development, Steve Nurnberg and Vice President of ... to the company. Dr. Bready served as ...
Breaking Biology News(10 mins):